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Background: Dual-use catheters for chemotherapy and
hematopoetic progenitor cell collection are increasingly used
in the pediatric autologous transplant population. Published
data for beneﬁts and complications with these lines is
limited. We evaluated the use of various collection line
strategies before and after an institutional change to the
Power Hickman dual-use line to determine advantages and
disadvantages.
Methods: We reviewed 65 collection episodes over a 5 year
period comparing 3 groups: Power Hickman, Muhurkar
dialysis catheter, and peripheral IV. We assessed variables in
the categories of efﬁciency, complications, and cost.
Results: The Power Hickman was found to be more efﬁcient
than the Muhurkar for several variables including need for
second anesthesia for line placement and number of collec-
tion days. No differences were found among the groups for
complications. A cost advantagewas suggested for the Power
Hickman and PIV over the Muhurkar.
Discussion: A dialysis catheter may still be required for some
patients due to their size and other variables. However, for
other groups, our data indicate that dual-use catheters are
a safe and efﬁcient option.
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Outcomes After Second Allogeneic Transplants in
Pediatric Patients With Relapsed Hematological
Malignancies
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Recurrence of hematological malignancies is one of the
most common indications for a second hemotopoeitic stem
cell transplant (HSCT). However there are limited outcomes
data after second HSCT in pediatric patients. We report the
results of second HSCT in 42 patients with relapsed lymphoid
(n-12) or myeloid (n-30) malignancies after ﬁrst HSCT per-
formed at our institution between 2000-2012. The median
age at the time of the second transplant was 7 years (range:
2-19 years). 20/42 patients had active disease at the time of
second transplant. The median time to relapse after a ﬁrst
transplant was 242 days (range: 138d-731d) for lymphoid
malignancies and 202.5days (range: 50d-1687d) for myeloid
malignancies. 20/42 received a haplo-identical donor
(haplo), 19/42 received a matched or mismatched unrelated
donor (MUD/MMUD) and 3/42 received a matched or mis-
matched related donor (MRD/MMRD). 16 patients had
myeloablative conditioning and 26 reduced intensityconditioning. Overall survival and disease free survival (DFS)
were 30% (13/42) and 26% (11/42), respectively with
a median follow up of 1496 days (range: 37d-3434d). 5/16 of
these survivors had received myeloablative conditioning
versus 6/26 who received reduced intensity conditioning.
The DFS by disease typewas 16% (2/12) for lymphoid and 30%
(9/30) for myeloid malignancies (MDS/AML, n¼6/10; AML,
n¼2/17; biphenotypic, n¼1/1), respectively. Patients with
MDS/AML had better outcome than patients with AML alone.
Survival also varied according to donor type (7/20 haplo, 4/19
MUD/MMUD, and 0/3 MRD/MMRD). Of the 11 disease free
survivors, 8 were in remission at the time of the second
transplant and 9 had relapsed >240 days post transplant.
Overall median survival was 4.6 years (range: 0.2-9.7 years).
The primary cause of death was relapse/persistent disease in
24/42 or infection/ GVHD in 7/42. Additionally, 7 of these
patients underwent a third HSCT for relapsed disease after
second HSCT and all 7 had active disease at time of third
transplant. No patients survived after a third transplant.
Hence 26% of relapsed patientsmay be long term disease free
survivors after a second HSCT from a haploidentical or
unrelated donor. Patients transplanted in full remission with
relapse >240 days after ﬁrst HSCT and a diagnosis of MDS/
AML are likely to be favorable prognostic factors.283
Outcomes in Pediatric Patients With Engraftment Failure
After Allogeneic Transplants
Swati Naik, Caridad Martinez, Catherine M. Bollard,
Javier Amin El-Bietar, Stephen Gottschalk, Kathryn Leung,
Nabil M. Ahmed, Carl Allen, Helen E. Heslop,
Malcolm K. Brenner, Robert A. Krance. Center for Cell and Gene
Therapy, Baylor College of Medicine, Texas Children's Hospital,
Houston, TX
Graft failure is an uncommon but serious complication
after allogeneic haematopoeitic stem cell transplantation
(HSCT) and is an indication for a 2nd HSCT. However, there
are limited outcomes data for pediatric patients who
undergo such therapy. We now report on 44 pediatric
patients who had a 2nd HSCT after graft failure following
HSCT for malignant (n¼14) or non-malignant diseases
(n¼30) at our institution between 2000-2012. Primary graft
failure was deﬁned as failure to achieve ANC >0.5x10 9 /L for
3 consecutive days by day +30 (day +42 for cord donors) or
donor chimerism <5% (n¼22) and secondary graft failure
was deﬁned as loss of chimerism to <5% after having ach-
ieved >5%, or ANC persistently below 0.5x10 9 /L or platelet
count <20 x109/L (n¼23). The median age at ﬁrst transplant
was 6 yrs (range 1month to 21 years), 18 pts were trans-
planted from a matched or mismatched unrelated donor
(MUD/MMUD); 16pts from haplo-identical donor (haplo),
and 10 from a matched or mismatched related donor (MRD/
MMRD). Donor stem cell products were: marrow for 26
patients; peripheral blood (PB) for 17 patients and a cord
blood unit (CBU) for 1 patient. 26 patients received mye-
loablative conditioning (MAC); 17 reduced-intensity condi-
tioning (RIC) and 1 patient received no conditioning. The
median time between 1st and 2nd HSCT was 55 days (range:
30d-2587d) for patients with malignancies and 66 days
(range: 33d-1846d) for patients with non-malignant disor-
ders. The donor was the same for both the 1st and 2nd
transplant for 34 pts. More patients received PB stem cell
products for their second transplant (marrow product¼17,
